OncoMatch/Clinical Trials/NCT06291064

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Is NCT06291064 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for triple negative breast cancer.

Phase 2RecruitingUniversity of ChicagoNCT06291064Data as of May 2026

Treatment: Cyclophosphamide · Epirubicin · Docetaxel · Carboplatin · Capecitabine — The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Biomarker criteria

Required: ESR1 low estrogen receptor expression (< 20%) (< 20%)

low estrogen reception (ER) expression (< 20%)

Required: PR (PGR) negative (negative)

progesterone receptor (PR) negative

Required: HER2 (ERBB2) negative (negative)

human epidermal growth factor 2 (HER2) negative

Disease stage

Required: Stage IIA, IIB, IIIA, IIIB, IIIC (AJCC 2009)

Clinical stages IIA -IIIC (AJCC 2009)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Granulocyte ≥ 1,500/microliter; Platelet count ≥ 100,000/microliter; ANC ≥ 1,500/microliter; Hemoglobin ≥ 10g/dL

Kidney function

Creatinine within institutional normal limits or GFR ≥ 30 mL/min/1.73 m2 by CKD EPI equation

Liver function

Bilirubin ≤ 1.5 x ULN; AST/ALT < 2.5 x ULN

Cardiac function

Baseline left ventricular ejection fraction ≥ 55%

Granulocyte ≥ 1,500/microliter; Platelet count ≥ 100,000/microliter; ANC ≥ 1,500/microliter; Hemoglobin ≥ 10g/dL; Bilirubin ≤ 1.5 x ULN; AST/ALT < 2.5 x ULN; Creatinine within institutional normal limits or GFR ≥ 30 mL/min/1.73 m2 by CKD EPI equation; Baseline left ventricular ejection fraction ≥ 55%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify